Pharma BD Deal Intelligence
Strong initial integration and synergy capture, but IVAX-built US generics scale ultimately sat inside the reporting unit that took a $16.5B impairment a decade later — a foundational deal whose long-run value is genuinely mixed, not a clean win.
Full analysis, sources & comparables →FTC required Teva and IVAX to divest 15 generic products to Par Pharmaceutical and Barr Pharmaceuticals to remedy competitive overlap before allowing the…
Analysts framed the IVAX deal as Teva's pivot from regional generics player to global #1, but flagged execution risk in integrating IVAX's Latin American…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Generic pharma; deal announced 2005-07, completed 2006-01-26 making Teva world's largest generics company
Strong initial integration and synergy capture, but IVAX-built US generics scale ultimately sat inside the reporting unit that took a $16.5B impairment a decade later — a foundational deal whose long-run value is genuinely mixed, not a clean win.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation (this deal) | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 2006 deals · Teva Pharmaceutical Industries Ltd. deals